Anabolic steroid abuse and toxicology
1992; Wiley; Volume: 22; Issue: 4 Linguagem: Inglês
10.1111/j.1445-5994.1992.tb02151.x
ISSN0004-8291
Autores Tópico(s)Sexual Differentiation and Disorders
ResumoAustralian and New Zealand Journal of MedicineVolume 22, Issue 4 p. 374-381 Anabolic steroid abuse and toxicology M.C. Kennedy, Corresponding Author M.C. Kennedy Honorary Research Associate, Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Sydney; Visiting Medical Officer Physician, Manly Hospital, Sydney, NSWDr M.C. Kennedy, Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Darlinghurst, NSW 2010, AustraliaSearch for more papers by this author M.C. Kennedy, Corresponding Author M.C. Kennedy Honorary Research Associate, Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Sydney; Visiting Medical Officer Physician, Manly Hospital, Sydney, NSWDr M.C. Kennedy, Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Darlinghurst, NSW 2010, AustraliaSearch for more papers by this author First published: August 1992 https://doi.org/10.1111/j.1445-5994.1992.tb02151.xCitations: 16AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Saartok T., Dahlberg E., Gustafsson JA. Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. Endocrinol 1984; 114: 2100– 6. 2 Bergink EW, Geelen JAA, Turpijn EW. Metabolism and receptor binding of nandrolone and testosterone under in vitro and in vivo conditions. Acta Endocrinol 1985; Suppl 271: 31– 7. 3 Liao S., Liang T., Fang S.. Castaneda E., Shao T-C. Steroid structure and androgenic activity. J Biol Chem 1973; 248: 6154– 62. 4 Honrath WL, Wolff A., Melo A.. The influence of the amount of solvent (sesame oil) on the degree and duration of action of subcutaneously administered testosterone and its propionate. Steroids 1963; 2: 425– 8. 5 Caminos-Torres R., Ma L., Snyder PJ. Testosterone-induced inhibition of the LH and FSH responses to gonadotrophin-releasing hormone occurs slowly. J Clin Endocrinol Metab 1977; 44: 1142– 53. 6 Gooren LJG. Long-term safety of the oral androgen testosterone undecanoate. Int J Androl 1986; 9: 21– 5. 7 Foss GL. The oral application of methyl testosterone and its simplification of androgen therapy. Brit Med J 1939; 1: 11– 2. 8 Masse R., Ayotte C., Honggang BI, Dugal R.. Studies on anabolic steroids. III. Detection and characterization of stanozolol urinary metabolites in humans by gas chromatography-mass spectrometry. J Chromatogr 1989; 479: 17– 37. 9 Pappo R., Jung CJ. 2-Oxasteroids: a new class of biologically active compounds. Tetrahedron Len 1962; 2: 365– 71. 10 Council Report. Medical and non-medical uses of anabolic-androgenic steroids. J Am Med Assoc 1990; 264: 2923– 7. 11 Buckley WE, Yesalis CE, Friedl KE, Anderson WA, Streit AL, Wright JE. Estimated prevalence of anabolic steroid use among male high school seniors. J Am Med Assoc 1988; 26: 3441– 5. 12 US Olympic Committee. Sportsmediscope 1988; 7. 13 Windsor R., Dumitru D.. Prevalence of anabolic steroid use by male and female adolescents. Med Sc Sports Exerc 1989; 21: 494– 6. 14 Lindstrom M., Nilsson AL, Katzman PL, Janzon LJ, Dymling J-F. Use of anabolic-androgenic steroids among body builders – frequency and attitudes. J Intern Med 1990; 227: 407– 11. 15 Scarpino V., Arrigo A., Benzi G. et al. Evaluation of prevalence of 'doping' among Italian athletes. Lancet 1990; 336: 1048– 50. 16 Webb J.. Survey of drug use in Australian Sport. Sports Coach 1988; 12: 9– 10. 17 Taylor WN, Black AB. Pervasive anabolic steroid use among health club athletes. Ann Sports Med 1987; 3: 155– 9. 18 Freed, DLJ, Banks AJ, Longson D.. Burley DM. Anabolic steroids in athletics: crossover double-blind trial on weightlifters. Brit Med J 1975; 2: 471– 3. 19 Boel J., Andersen LB, Rasmussen B., Hansen SH, Dossing M.. Hepatic drug metabolism and physical fitness. Clin Pharm Ther 1984; 36: 121– 6. 20 Hervey GR, Knibbs AV, Burkinshaw L. et al. Effects of methandienone on the performance and body composition of men undergoing athletic training. Clin Sci 1981; 60: 457– 61. 21 Crist DM, Stackpole PJ, Peake GT. Effects of androgenic-anabolic steroids on neuromuscular power and body composition. J Appl Physiol 1983; 54: 366– 70. 22 Casner SW, Early RG, Carlson BR. Anabolic steroid effects on body composition in normal young men. J Sports Med 1971; 11: 98– 102. 23 Ward P.. The effect of an anabolic steroid on strength and lean body mass. Med Sci Sports 1973; 5: 277– 82. 24 Forbes GB. The effect of anabolic steroids on lean body mass: the dose response curve. Metabolism 1985; 34: 571– 3. 25 O'Shea JP. Anabolic steroid: effects on competitive swimmers. Nutr Rep Intern 1970; 1: 337– 42. 26 Johnson L.C, O'Shea J.P. Anabolic steroid: Effects on strength development. Science 1969; 164: 957– 9. 27 Hervey GR, Hutchinson I., Knibbs AV et al. 'Anabolic' effects of methandienone in men undergoing athletic training. Lancet 1976; 2: 699– 702. 28 Johnson LC, Fisher G., Silvester LJ, Hofheins CC. Anabolic steroid: effects on strength, body weight, oxygen uptake and spermatogenesis upon mature males. Med Sci Sports 1972; 4: 43– 5. 29 Fahey TD, Brown HC. The effects of an anabolic steroid on the strength, body composition, and endurance of college males when accompanied by a weight training program. Med Sci Sports 1973; 5: 272– 6. 30 Johnson IC, Roundy ES, Allsen PE, Fisher AG, Silvester LJ. Effect of anabolic steroid treatment on endurance. Med Sci Sports 1975; 7: 287– 9. 31 Hakkinen K., Alen M.. Physiological performance, serum hormones, enzymes and lipids of an elite power athlete during training with and without androgens and during prolonged detraining. A case study. J Sports Med 1986; 26: 92– 100. 32 Haupt HA, Rovere GD. Anabolic steroids: a review of the literature. Am J Sports Med 1984; 12: 469– 84. 33 Elashoff JD, Jacknow AR, Shain SG, Braunstein GD. Effects of anabolic androgenic steroids on muscular strength. Ann Intern Med 1991; 115: 387– 93. 34 Ariel G., Saville W.. Anabolic steroids: the physiological effects of placebos. Med Sci Sports 1972; 4: 124– 6. 35 Jarow JP, Lipshultz LI. Anabolic steroid-induced hypogonadotrophic hypogonadism. Am J Sports Med 1990; 18: 429– 31. 36 Strauss RH, Liggett MT, Lanese RR. Anabolic steroid use and perceived effects in ten weight-trained women athletes. J Am Med Assoc 1985; 253: 2871– 3. 37 Holmberg D.. The effect of drugs on human placenta enzyme activities. Proc XVI Scandinavian Congress of Physiology and Pharmacology. Acta Physiologica Scandinavica 1979; Suppl 473: 260. 38 Tuchmann-Duplessis H.. Drug effects on the fetus. In: Monographs on Drugs 1, Vol 2. New York : Adis Press 1977, 209– 29. 39 Joss E., Zuppinger K.. Oxandrolone in girls with Turner's syndrome. Acta Paed Scand 1984; 73: 674– 9. 40 Limbeck GA, Rogelio HA, Ruvalcaba RHA, Mahoney CP, Kelley VC. Studies on anabolic steroids. IV. The effects of oxandrolone on height and skeletal maturation in uncomplicated growth retardation. Clin Pharm Therapeut 1971; 12: 798– 805. 41 Foss GI, Simpson SL. Oral methyltestosterone and jaundice. Brit Med J 1959; 1: 259– 63. 42 Small M., Forbes CD, MacCuish AC. Metabolic effects of stanozolol in type II diabetes mellitus. Horm Metabol Res 1986; 18: 647– 8. 43 Landon J., Wynn BJ, Cooke JNC. Effects of anabolic steroid methandienone on carbohydrate metabolism in man. II. Effect of methandienone on response to glucagon adrenalin and insulin in the fasted subject. Metabolism 1962; 11: 513– 23. 44 Landon J., Wynn BJ, Cooke JNC, Kennedy A.. Effects of anabolic steroid, methandienone on carbohydrate metabolism in man. Metabolism 1962; 11: 501– 12. 45 Cohen JC, Hickman R.. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. J Clin Endocrinol Metab 1987; 64: 960– 3. 46 Shephard RJ, Killinger D., Fried T.. Responses to sustained use of anabolic steroid. Brit J Sports Med 1977; 11: 170– 3. 47 Hurley BF, Seals DR, Hagberg JM et al. High density lipoprotein cholesterol in bodybuilders v powerlifters. J Am Med Assoc 1984; 252: 507– 13. 48 Lenders JWM, Demacker PNM, Vos JA et al. Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur body builders. Int J Sports Med 1988; 9. 19– 23. 49 Kleiner SM, Calabrese LH, Fielder KM, Naito HK, Skibinski CI. Dietary influences on cardiovascular disease risk in anabolic steroid-using and nonusing bodybuilders. J Am Coll Nutr 1989; 8: 109– 119. 50 Thompson PD, Cullinane EM, Sady SP et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. J Am Med Assoc 1989; 261: 1165– 8. 51 Alen M., Rahkila P., Reinila M., Vihko R.. Androgenic-anabolic steroid effects on serum thyroid, pituitary and steroid hormones in athletes. Am J Sports Med 1987; 15: 357– 61. 52 Fujioka M., Shinohara Y., Baba S., Irie M., Inoue K.. Acute suppression of endogenous testosterone levels by exogenous testosterone in normal men. Life Sci 1987; 41: 945– 9. 53 Alen M., Reinila M., Vihko R.. Response of serum hormones to androgen administration in power athletes. Med Sci Sports Exerc 1985; 17: 354– 9. 54 Molteni A., Brownie AC, Skelton, FR. Production of hypertensive vascular disease in the rat by methyltestosterone. Lab Invest 1969; 21: 129– 37. 55 Urhausen A., Holpes, R., Kindermann W.. One- and two-dimensional echocardiography in bodybuilders using anabolic steroids. Europ J Appl Physiol 1989; 58: 633– 40. 56 Zuliani U., Bernardini B., Catapano A., Campana M., Cerioli G., Spatini. Effects of anabolic steroids, testosterone and HGH on blood lipids and echocardiographic parameters in body builders. Int J Sports Med 1989; 10: 62– 7. 57 Frankle MA, Eichberg R., Zachariah SB. Anabolic androgenic steroids and a stroke in an athlete: case report. Arch Phys Med Rehabil 1988; 69: 632– 3. 58 Mochizuki RM, Richter KJ. Cardiomyopathy and cerebrovascular accident associated with anabolic-androgenic steroid use. Physician Sports Med 1988; 16: 109– 14. 59 McNutt RA, Ferenchick GS, Kirlin PC, Hamlin NJ. Acute myocardial infarction in a 22 year old world class weight lifter using anabolic steroids. Am J Cardiol 1988; 62: 164. 60 Bowman SJ, Tanna S., Fernando S., Ayodeji A., Weatherstone RM. Anabolic steroids and infarction. Brit Med J 1989; 299: 632. 61 Ferenchick GS. Are androgenic steroids thrombogenic N Engl J Med 1990; 322: 476. 62 Luke JL, Farb A., Virmani R., Sample RHB. Sudden cardiac death during exercise in a weight lifter using anabolic androgenic steroids: pathological and toxicological findings. Case report. J Forensic Sci 1990; 35: 1441– 7. 63 Laroche GP. Steroid anabolic drugs and arterial complications in an athlete – a case history. Angiology 1990; 41: 964– 9. 64 Nagelberg SB, Laue L., Loriaux DL, Liu L., Sherins RJ. Cerebrovascular accident associated with testosterone therapy in a 21 year old hypogonadal man. N Engl J Med 1986; 314: 649– 50. 65 Shiozawa Z., Yamada H., Mabuchi C. et al. Superior sagittal sinus thrombus associated with androgen therapy for hypoplastic anaemia. Ann Neurol 1982; 12: 578– 80. 66 Graham S., Kennedy M.. Recent developments in the toxicology of anabolic steroids. Drug Saf 1990; 5: 458– 76. 67 Vest SA, Howard JE. Clinical experiments with the use of male sex hormones. J Urol 1938; 40: 154– 83. 68 Simonson E., Kearns WM, Enzer N.. Effect of methyl testosterone treatment on muscular performance and the central nervous system of older men. J Clin Endocrinol 1944; 4: 528– 34. 69 Gherondache CN, Dowling WJ, Pincus G.. Metabolic changes induced in elderly patients with an anabolic steroid (oxandrolone). J Geront 1967; 22: 290– 300. 70 Ariel G., Saville W.. The effect of anabolic steroids on reflex components. Med Sci Sports 1972; 4: 120– 3. 71 Altschule MD, Tillotson KJ. The use of testosterone in the treatment of depressions. New Engl J Med 1948; 239: 1036– 8. 72 Wilson IC, Prance AJ, Lara PP. Methyltestosterone with imipramine in men: conversion of depression to paranoid reaction. Am J Psychiatry 1974; 131: 21– 24. 73 Annito WJ, Layman WA. Anabolic steroids and acute schizophrenic episode. Case report. J Clin Psychiatry 1980; 41: 143– 4. 74 Pope HG, Katz DL. Body builders psychosis. Lancet 1987; 1: 863. 75 Pope HG, Katz DL. Affective and psychotic symptoms associated with anabolic steroid use. Am J Psychiatry 1988; 145: 487– 9. 76 Tennant F., Black DL, Voy RO. Anabolic steroid dependence with opioid features. New Engl J Med 1988, 319: 578. 77 Browner KJ, Blow FC, Beresford TP, Feulling C.. Anabolic-androgenic steroid dependence, J Clin Psychiatry 1989; 50: 31– 3. 78 Hays LR, Littleton S., Stillner V.. Anabolic steroid dependence. Am J Psychiatry 1990; 147: 122. 79 Vesselinovitch SD, Mihailovich N., Rao KVN. Potential role of synthetic sex steroids in hepatocarcinogenesis. In: Drugs in competitive athletes. JR Shipe, J. Savoury, (Eds). Oxford : Blackwell Scientific Publications, 1988, 97– 106. 80 Recant L., Lacy P.. Franconi's anaemia in hepatic cirrhosis. Am J Med 1965; 39: 466– 75. 81 Westaby D., Portman B., Williams R.. Androgen related primary hepatic tumors in non-Fanconi patients. Cancer 1983; 51: 1947– 52. 82 Carrasco D., Pallardo L., Prieto M., Moll JL, Cruz JM, Berenguer J.. Hepatic adenomata and androgenic treatment. Ann Intern Med 1984; 100: 316. 83 Overly WL, Dankoff JA, Wang BK, Singh UD. Androgens and hepatocellular carcinoma in an athlete. Ann Intern Med 1984; 100: 158– 9. 84 Goldman B.. Liver carcinoma in an athlete taking anabolic steroids. Internat Amer Osteopath Assoc 1985; 82: 56. 85 Creagh TM, Rubin A., Evans DJ. Hepatic tumours induced by anabolic steroids in an athlete. J Clin Path 1988; 41: 441– 3. 86 Bagheeri SA, Boyer JL. Peliosis hepatis associated with androgenic-anabolic steroid therapy. Ann Intern Med 1974; 81: 610– 8. 87 Roberts JT, Essenhigh DM. Adenocarcinoma of prostate in 40 year old bodybuilder. Lancet 1986; 2: 742. 88 Prat J., Gray GF, Stolley PD, Coleman JW. Wilms' tumor in an adult associated with androgen abuse. J Am Med Assoc 1977; 237: 2322– 3. 89 Edis AJ, Levitt M.. Anabolic steroids and colonic cancer. Med J Aust 1985; 142: 426– 7. 90 Kiraly CL, Collan Y., Alen M.. Effect of testosterone and anabolic steroids on the size of sebaceous glands in power athletes. Am J Dermatopathol 1987; 9: 515– 9. 91 Mayerhausen W., Riebel B.. Acne fulminans following application of anabolic agents. Zeitschrift für Hautkrankheiten 1989; 64: 875– 80. 92 Gebauer K., Cox J.. Acne scars after use of anabolic steroids. Brit Med J 1990; 300: 342. 93 Friedl KE, Yesalis CE. Self-treatment of gynaecomastia in bodybuilders who use anabolic steroids. Physician Sportsmed 1989; 17: 67– 79. 94 Aiache AE. Surgical treatment of gynaecomastia in the body builder. Plastic Reconstr Surg 1989; 83: 61– 66. 95 Calabbrese LH, Kleiner SM, Barrna BP et al. The effects of anabolic steroids and strength training on the human immune response. Med Sci Sports Exerc 1989; 21: 386– 92. 96 Scott MJ, Scott MJ Jnr. HIV infection associated with injections of anabolic steroids. J Am Med Assoc 1989; 262: 207– 8. 97 Sklarek HM, Mantouani RP, Erens E., Heisler D., Neiderman MS, Fein AM. AIDS in a body builder using anabolic steroids. New Engl J Med 1984; 311: 1701. Citing Literature Volume22, Issue4August 1992Pages 374-381 ReferencesRelatedInformation
Referência(s)